Moreover, this was corroborated by the projected cumulative 5-y OS (high exhibited 58.3% versus low with 78.1%) and 5-y PFS (high exhibited 55.4% versus low with 75.3%) rates for breast carcinoma patients presenting varying levels of HSP60 expression. This evidence concerns the gene HSPD1 and breast carcinoma.